Clinical Report: FDA Approves First Oral PCSK9 Inhibitor
Overview
The FDA has approved enlicitide (LIPFENDRA) as the first oral PCSK9 inhibitor for reducing LDL cholesterol in adults with hypercholesterolemia. This approval is based on reductions in LDL-C observed in phase 3 trials.
Background
Hypercholesterolemia is a major risk factor for cardiovascular disease, necessitating effective treatments to lower LDL cholesterol levels. PCSK9 inhibitors have emerged as a class of lipid-lowering agents, with the approval of enlicitide marking a new option for patients requiring additional LDL-C reduction.
Data Highlights
| Trial | Placebo-Adjusted LDL-C Reduction | Adverse Reactions |
|---|---|---|
| CORALreef Lipids | 56% at week 24 | Similar rates between groups |
| CORALreef HeFH | 59% at week 24 | Diarrhea in 7% vs 2%, Dizziness in 9% vs 4% |
Key Findings
- Enlicitide is the first FDA-approved oral PCSK9 inhibitor.
- It is indicated as an adjunct to diet and exercise for adults with hypercholesterolemia.
- In CORALreef Lipids, enlicitide showed a 56% placebo-adjusted reduction in LDL-C at week 24.
- In CORALreef HeFH, a 59% placebo-adjusted reduction in LDL-C was observed.
- Adverse reaction rates were similar between enlicitide and placebo groups.
- An ongoing trial is assessing the impact of enlicitide on cardiovascular morbidity and mortality.
Clinical Implications
Monitoring for gastrointestinal side effects, such as diarrhea and dizziness, may be necessary.
Conclusion
Enlicitide is an oral PCSK9 inhibitor approved for adults with hypercholesterolemia, pending further data on its long-term cardiovascular outcomes.
Related Resources & Content
- Merck, Press Release, 2023 -- FDA Approves First Oral PCSK9 Inhibitor
- New England Journal of Medicine, 2026 -- A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
- American Heart Association, 2026 -- 2026 Guideline on the Management of Dyslipidemia
- European Journal of Preventive Cardiology — Impact of PCSK9 inhibitors on lipoprotein(a) levels: a multi-centre study
- Endocrine Reviews — The Biology and Clinical Implications of PCSK7
- JAMA Network Open — Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis
- European Journal of Preventive Cardiology — Exploring the Role of PCSK9 Inhibitors in Reducing Lipoprotein(a) Levels: Is There More to Uncover?
- 2026 Guideline on the Management of Dyslipidemia - Professional Heart Daily | American Heart Association
- A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide | New England Journal of Medicine
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
